Welcome & introduction: Irene Ghobrial, George Vassiliou, Matt Davids & Shaji Kumar

Keynote talk 1: Title TBC: TBC

Plenary session 1: Classification
Chairs: Luca Malcovati & Ari Melnick

• Genomic landscape of multiple myeloma and of its precursor conditions: Jean-Baptiste Alberge
• Epigenetics in the transition between MGUS and MM: Felipe Prósper
• Genetics of MBL to CLL transition: Catherine Wu
• Distinguishing CCUS & MDS – morphology or genes?: Sanam Loghavi
• CHIP and ALL – what do we know and what should we know?: Lourdes Mendez

Panel discussion

Plenary session 2: Early detection, screening & risk stratification
Chairs: Niccolò Bolli & Susan Slager

• Familial risk of CLL: TBC
• Screening in MGUS: Sigurdur Yngvi Kristinsson
• AI & CHIP/CCUS opportunities: Matteo Della Porta
• Evolution of risk stratification of SMM: Shaji Kumar
• Using AI to improve risk stratification: TBC
• Which prognostic tool to use for CHIP/CCUS?
  • Clonal hematopoiesis risk score (CHRS): Lachelle Weeks
  • Clonal cytopenia risk score (CCRS): Zhuoer Xie

Panel discussion

Break

Breakout session 1

 

---

 

SMM/MGUS/MM track: Screening and risk stratification
Chairs: Paola Neri & Shaji Kumar

• Screening for monoclonal gammopathy: Update on the PROMISE study: Catherine Marinac
• Immunological tools for assessing risk of disease progression: Romanos Sklavenitis-Pistofidis
• Utilizing PANGEA for risk stratification of MGUS and SMM: TBC
• Risk stratification in SMM – the IMWG 2/20/20 model: Efstathios Kastritis

Panel discussion: Catherine Marinac, Adam Sperling, Efstathios Kastritis, Shaji Kumar, Irene Ghobrial

 

---

 

CHIP/CCUS/MDS/AML track: Translational studies in clonal hematopoiesis
Chairs: Amer Zeidan & Iannis Aifantis

• Does the immune system recognise clonal hematopoiesis mutations?: TBC
• Telomerase activity and clonal hematopoesis: Coleman Lindsley
• Gene editing to model clonal hematopoiesis: Ravi Majeti

Panel discussion

 

---

 

MBL/CLL/lymphoma track: Precursor to malignancy transition
Chairs: TBC & Dinis Calado

• Tracing founder mutations in follicular lymphoma precursors: Sandrine Roulland
• New perspectives on the classification/definition of MBL: Aswin Sekar
• Natural selection of B cells – friend or foe? Ari Melnick
• Autonomous B-cell receptor signaling and genetic aberrations in familial MBL/CLL: Hendrik Veelken

Panel discussion

Welcome reception

Welcome to Day 2: Jesús San Miguel & Shaji Kumar

Keynote talk 2: Reframing (Renaming?) MDS and CHIP: Neal Young

Keynote talk 3: Emerging role for context relevant clonal hematopoiesis clinics in academic centers: Mrinal Patnaik

Plenary session 3: To treat or not to treat?
Chairs: Jesús San Miguel & TBC

• Debate 1 – We should treat high-risk smoldering multiple myeloma and MGUS
  • For: Shaji Kumar
  • Against: Nizar Bahlis
    
• Debate 2 – We should treat CHIP and CCUS
  • For: George Vassiliou
  • Against: David Steensma
• Debate 3 – We should treat MBL
  • For: TBC
  • Against: TBC

Panel discussion

Plenary session 4: Designing pre-cursor clinical trials
Chairs: Saad Usmani & Uma Borate

• Talk title TBC (SMM/MGUS/MM perspective): Ken Anderson
• Talk title TBC (CHIP/CCUS/MDS/AML perspective): Uma Borate
• Talk title TBC (MBL/CLL/lymphoma perspective): Paolo Ghia
• Talk title TBC (The patient perspective): Jenny Ahlstrom

Panel discussion

Break

Breakout session 2

 

---

 

SMM/MGUS/MM track: Evaluating different endpoints in SMM/MGUS trials
Chairs: Pieter Sonneveld & Catherine Marinac

• The use of biochemical progression as an endpoint: Adam Sperling
• The use of CR / MRD as an accelerated endpoint: Nisha Joseph
• The use of QoL & toxicity over time in precursor trials: Betsy O’Donnell

Panel discussion: Pieter Sonneveld, Catherine Marinac, Irene Ghobrial, Nisha Joseph, Betsy O’Donnell& Ken Anderson, Hira Mian

 

---

 

CHIP/CCUS/MDS/AML track: Practical considerations in patients with clonal hematopoiesis
Chairs: Lachelle Weeks & Sanam Loghavi

• Case 1 – CHIP patient with solid tumor cancer
  • Panel discussion: Kelly Bolton, Mrinal Patnaik
• Case 2 – Patient with high-risk CCUS
  • Panel discussion: Catherine Cargo, Uma Borate
• Case 3 – Patient with donor-derived clonal hematopoiesis
  • Panel discussion: Lourdes Mendez, Coleman Lindsley

Panel discussion

 

---

 

CLL/MBL/lymphoma track: Novel tools to explore the biology of malignant transformation
Chairs: Sandrine Roulland & Paolo Ghia

• Novel testing approaches for clonality diagnostics in suspected lymphoproliferative disorders: Anton Langerak
• Single cell multi-omics in MBL: Giovanni Tonon
• Mouse models of lymphoma progression: Dinis Calado
• 3D culture systems to model the leukemia microenvironment in vitro: Cristina Scielzo

Panel discussion

Lunch

Breakout session 3

 

---

 

SMM/MGUS/MM track: Latest clinical trials and evidence generation
Chairs: TBC & Salomon Manier

• Curative approaches: TBC
• Preventative approaches: Meletios Dimopoulos
• Phase II trials and immunotherapy approaches in SMM: Omar Nadeem
• Non-drug interventions in SMM/MGUS: Diet and lifestyle: Urvi Shah
• Which treatment should you choose for your high-risk SMM patient?
  • Daratumumab: Meletios Dimopoulos
  • Lenalidomide: Angela Dispenzieri

Panel discussion

 

---

 

CHIP/CCUS/MDS/AML track: Clinical studies in clonal hematopoiesis
Chairs: Amer Zeidan & Kelly Bolton

• Targeting the inflammasome in high-risk clonal hematopoiesis: Uma Borate
• Utilizing vitamin C for clonal hematopoiesis: Kirsten Grønbæk
• What we can learn about clonal hematopoiesis from large interventional studies: David Steensma
• Talk title TBC: Kelly Bolton

Panel discussion

 

---

 

CLL/MBL/lymphoma track: Clinical investigations in precursor conditions
Chairs: Matthew Davids & Carsten Niemann

• Updates in MBL: Andrew Rawstron
• Relationship between immunity and MBL: Miguel Alcoceba Sánchez
• Updates on vaccination as an early intervention strategy in CLL: Marwan Kwok
• Updates on machine learning and early intervention strategies: Carsten Niemann

Panel discussion

Break

Keynote talk 4: FDA – endpoints and trial designs in precursor conditions: Bindu Kanapuru

Plenary session 5: Defining response criteria
Chairs: TBC & TBC

• Defining new endpoints for clinical trials in smoldering myeloma: Irene Ghobrial
• Talk title TBC: Zhuoer Xie
• Talk title TBC: TBC

Panel discussion: Irene Ghobrial, Zhuoer Xie, TBC, and Bindu Kanapuru

Plenary session 6: Latest from clinical trials I
Chairs: Kelly Bolton & TBC

• Why should we intervene in precursor diseases: Jesús San Miguel
• Why an early timepoint of MRD would matter in SMM: Pieter Sonneveld
• CDK4/6 inhibitors to prevent therapy-related TP53 CH expansion: Kelly Bolton
• Update on early intervention in CLL: Matt Davids

Panel discussion

Day 2 wrap up

Faculty dinner

Welcome to Day 3: Amer Zeidan & Matthew Davids

 

Keynote talk 5: Clonal hematopoiesis and non-haematological disease: Siddhartha Jaiswal  

Plenary session 7: Latest from clinical trials II
Chairs: Pieter Sonneveld & TBC

• Talk title TBC: TBC
• Talk title TBC (CHIP/CCUS): Luca Malcovati
• Risk adapted approaches to intervention in SMM: Kwee Yong

Panel discussion

Break

Plenary session 8: Stakeholder panel discussion
Chairs: George Vassiliou & Irene Ghobrial

Panellists: Ken Anderson, Jenny Ahlstrom, Helgi Van De Velde, TBC

Plenary session 9: Breakout summaries, outcomes and initiatives
Chairs: George Vassiliou & Matthew Davids

• MBL/CLL/lymphoma track: Matthew Davids & Paolo Ghia
• SMM/MGUS/MM track: Shaji Kumar & Irene Ghobrial
• CHIP/CCUS/MDS/AML track: George Vassiliou & Amer Zeidan

Panel discussion

Meeting summary and close: Irene Ghobrial, George Vassiliou, Matt Davids & Shaji Kumar